6505--Carbidopa Levodopa Immediate Release (IR) Tablets

The Department of Veterans Affairs National Acquisition Center is soliciting offers for Carbidopa/Levodopa Immediate Release (IR) Tablets under solicitation number 36E79726R0008. This pharmaceutical procurement seeks to establish a contract for various strengths and package sizes of Carbidopa/Levodopa IR Tablets to support the VA, Department of Defense, Bureau of Prisons, and Indian Health Service. Offerors must submit pricing for a base year plus four one-year option periods and provide a unique 11-digit National Drug Code (NDC) for each product offering, with all pricing to include a 0.5% Cost Recovery Fee. The solicitation requires products to meet specific FDA manufacturing requirements and packaging specifications across six line items representing different tablet strengths (10mg/100mg and 25mg/100mg) and package sizes (100, 500, and 1,000 tablets per bottle). The original deadline for receipt of offers was January 27, 2026, but an amendment issued on January 9, 2026 (effective January 22, 2026) extended the deadline to February 3, 2026 at 2:30 PM Central Standard Time. Offerors must acknowledge receipt of this amendment prior to submission or risk rejection of their proposals.

This solicitation is designated as a small business set-aside with a size standard of 1,300 employees, making it available only to small business concerns in the Pharmaceutical Preparation Manufacturing category (NAICS 325412). One aggregate award is anticipated across the six line items. The government files provided do not specify estimated annual quantities or total contract values; however, the structure indicates significant pharmaceutical supply requirements across multiple federal agencies over the five-year contract period. Performance will be fulfilled through the provision of pharmaceuticals meeting FDA standards, with the contracting officer for this acquisition identified as Nicholas I. McGregor of the VA's National Acquisition Center located at Hines, Illinois.